



**pulsehealth**

1H17 Investor Presentation

February 2017

Presented by  
Phillipa Blakey, MD & CEO  
Mark Hays, CFO



# Pulse Overview

*- An emerging  
healthcare  
growth  
company*

- Niche operator of **specialist private hospitals** and **day surgeries**
  - Specialist surgical hospitals
  - Mental health hospitals
  - Rehabilitation hospitals
- Operating in NSW, QLD, VIC and NZ
- Eight **hospitals** and five **day surgeries**
- **Gold Coast Surgical Hospital** greenfield ramp-up continuing
  - Strong medium and long term growth asset



# Pulse Corporate Overview

Share Price - 3yr



Snapshot at 22 February 2017

ASX:PHG	
<b>Sector</b>	<b>Health Care</b>
Listed	Nov 2003
Dividend yield	NA
Dividend franking	NA
52 week high	\$0.460
52 week low	\$0.205

Enterprise Value 22 February 2017

EV Breakdown	Current
<b>Share Price \$</b>	<b>0.455</b>
Shares on Issue (m)	257.1
Mkt Cap (\$m)	117.0
Net Debt (\$m)	28.7
EV \$m	145.7

Share Register at 22 February 2017

	Ownership <sup>(1)</sup>
Viburnum Funds	19.29%
Sante Capital Investments	15.86%
Colonial First State	7.70%
Macquarie Health and Throvena	6.91%
Other	50.24%
<b>Total</b>	<b>100.00%</b>

1. Percentages based on most recent Form 604 lodgments.



# Financial Highlights

- 1H17 group **revenue up 42%** to \$49.5m (1H16: \$34.9m)
  - Established hospitals revenue increased by 37% to \$46.4m (1H16: \$34.0m)
    - Contribution from recently acquired hospitals and day surgeries in 2016<sup>(1)</sup>: \$13.5m
    - Contribution from existing hospitals<sup>(2)</sup>: \$32.9m
  - Greenfield ramp-up of Gold Coast Surgical Hospital continuing with a revenue contribution of \$3.1m
- 1H17 underlying **EBITDA<sup>(3)</sup> growth from established hospitals and day surgeries of 59%**, to \$7.2m (1H16: \$4.5m)
  - Contribution from existing hospitals: \$4.4m and this represents growth of 15% compared to 2H16 (1H16: \$4.5m)
- **NPAT (before significant items<sup>(3)</sup>) up 34%** to \$3.9m (1H16: \$2.9m)
- **Positive cash flows** from operating activities \$3.6m
- **FY17 underlying EBITDA<sup>(3)</sup> guidance** reaffirmed at between **\$13.5m and \$15.5m** for established hospitals and day surgeries

1. Recently acquired hospitals and day surgeries in 2016 include Boulcott Hospital, Healthwoods, and Hobson Day Surgeries


2. Existing hospitals include all established hospitals excluding recently acquired hospitals and day surgeries in 2016

3. Underlying figures exclude ramp-up costs associated with the Gold Coast Surgical Hospital, one-off costs of the proposed acquisition with HealthCare, one-off benefit of the deferred consideration of \$2.3m from acquisitions and other one-off items



# Pulse Facilities

- REHAB-PSYCH
- MED-SURG
- DAY-SURG



Facility	Location	Theatres	Beds
<b>Rehabilitation and Mental Health</b>			
Westmead Rehabilitation Hospital	NSW	-	65
The Hills Clinic	NSW	-	59
Eden Rehabilitation Hospital	QLD	-	48
Mackay Rehabilitation Hospital	QLD	-	34
<b>Medical Surgical</b>			
Forster Private Hospital	NSW	2	69
Gympie Private Hospital	QLD	2	40
Boulcott Hospital	New Zealand	4	29
Gold Coast Surgical Hospital	QLD	6	24
<b>Day Surgery</b>			
Bega Valley Private Hospital	NSW	1	-
Healthwoods Day Surgery	NSW	2	-
Hobson Healthcare (Altona)	VIC	1	-
Hobson Healthcare (Sydenham)	VIC	2	-
Hobson Healthcare (Werribee)	VIC	2	-
<b>Total</b>		<b>22</b>	<b>368</b>



# Gold Coast Surgical Hospital

- Total investment to date \$19.2m for building fit-out and equipment, and ramp up costs
- Revenue contribution \$3.1m representing 32% increase over 2H16
- Good progress being made:
  - The hospital continues to negotiate and secure contracts with other parties, and undertook its first contracted surgery list in February 2017. It expects to service 100 contracted patients before May, with more referrals expected in May and June.
  - The hospital is introducing a new ophthalmology service with highly respected local ophthalmologists. Once ramped up, the hospital expects to service 1,000 ophthalmology patients per year
  - Implemented tighter cost controls and an organisational restructure generating annual savings of c.\$500k
  - Accredited five new doctors in February 2017 and expect to continue to accredit several new doctors every month
- Anticipated to turn to profit in FY18, in line with previous guidance. Expected full year ramp up loss of c.\$4.5m due to:
  - Delay in commencement of contracts and partnership arrangements; and
  - Slower than expected onboarding of surgeons driven by the uncertainty caused by the potential transaction with Health Care



# Proposed Transaction with Healthe Care

- On 30 November 2016, Pulse announced an all cash proposal by Healthe Care to acquire 100% of the outstanding shares in Pulse for **\$0.47 per share** via a scheme of arrangement
- Pulse directors **unanimously recommend shareholders to vote in favour** of the scheme<sup>(1)</sup>
- Following its review of the company's 1H results and based solely on the information contained in the 1H results announcement, Healthe Care has confirmed to Pulse that the 1H results do not alter its intention to proceed with the Scheme on the terms set out in the scheme implementation deed.
- Pulse have asked Leadenhall Corporate Advisory Pty Ltd, the independent expert commissioned by the Company to opine on the Scheme, to update its opinion following release of the 1H results

1. Pulse directors' recommendation is subject to no superior proposal emerging and the independent expert continuing to conclude that the scheme is in the best interests of Pulse shareholders



# Operating Environment

- Facing short term headwinds due to weakening health insurance participation rate and growing policy exclusions
- Long term growth supported by continued **attractiveness of industry fundamentals**
- **Escalated ageing of population** with **growing chronic** and **degenerative disease burden** and **medical technology developments** making more procedures and interventions possible and desirable
  - Demand growth
  - Increased pressure on public hospitals
  - Government policies continue to incentivise private health insurance coverage



# Pulse Outlook

- FY17 **Underlying EBITDA<sup>(1)</sup>** guidance for established hospitals and day surgeries reaffirmed at between \$13.5m - \$15.5m
- Ramp-up losses associated with the Gold Coast Surgical Hospital expected to be c.\$4.5m in FY17, with profitability expected in FY18
- Continuing to progress proposed transaction with Healthe Care
  - Scheduled scheme meeting date: 22 March 2017
  - Scheduled scheme implementation date: 6 April 2017

1. Underlying EBITDA and NPAT (before significant items) excludes ramp-up costs associated with the Gold Coast Surgical Hospital and one-off costs of execution of our acquisition pipeline – Refer appendix 2.

# Appendix 1 – 1H17 Financial Performance



## Profit & Loss (underlying)

(\$'000)	1H17	1H16	
<b>Revenue</b>	<b>49,455</b>	<b>34,932</b>	▲
Growth	42%	29%	
<b>EBITDA-R</b>	<b>12,799</b>	<b>8,415</b>	▲
Growth	52%	45%	
<b>EBITDA (underlying<sup>(1)</sup>)</b>	<b>7,205</b>	<b>4,523</b>	▲
Margin	15%	13%	▲
Depreciation/Amortisation	(1,073)	(587)	
<b>EBIT (underlying)</b>	<b>6,132</b>	<b>3,936</b>	▲
Finance Costs	(957)	(599)	
<b>Profit before tax (underlying)</b>	<b>5,175</b>	<b>3,337</b>	▲
Tax	(1,247)	(397)	
<b>NPAT (underlying)</b>	<b>3,928</b>	<b>2,940</b>	▲

1. Underlying figures exclude ramp-up costs associated with the Gold Coast Surgical Hospital, one-off costs of the proposed acquisition with HealthCare, one-off benefit of the deferred consideration adjustment of \$2.3m from acquisitions and other one-off items

# Appendix 1 – 1H17 Financial Performance



## Cash flow

(\$'000)	1H17	1H16	
<b>Operating Cash flow</b>	<b>3,648</b>	<b>(1,825)</b>	<b>▲</b>
<u>Investing cash flows:</u>			
Payments for intangible assets	(15,217)	-	
Acquisitions – deferred consideration	(1,160)	(2,176)	
Capex – PPE	(1,790)	(9,264)	
Capex – proceeds sale of freehold	-	6,830	
Other investing cash flow	20	-	
Interest received	9	36	
<b>Total investing cash flow:</b>	<b>(18,138)</b>	<b>(4,574)</b>	
<u>Financing cash flow:</u>			
Equity (net of costs)	-	29,991	
Dividends paid	-	(493)	
Debt (net)	2,085	3,905	
<b>Total financing cash flow</b>	<b>2,085</b>	<b>33,403</b>	
Change in cash & cash equivalents	(12,405)	27,004	
Opening cash balance	16,648	3,491	
<b>Closing cash balance</b>	<b>4,243</b>	<b>30,495</b>	

# Appendix 1 – 1H17 Financial Performance



## Balance Sheet

(\$'000)	1H17	1H16	
Cash	4,243	30,495	
Other current assets	16,062	12,326	
PP&E	25,785	19,186	
Intangibles	98,167	61,041	
Total Assets	147,904	125,930	▲
Borrowings	32,901	27,885	
Payables, provisions and other	22,816	15,627	
Total Liabilities	55,717	43,512	▲
<b>Net Assets / Total Equity</b>	<b>92,187</b>	<b>82,418</b>	▲
NTA	(5,980)	21,377	
<b>NTA per share (cents)</b>	<b>(2.3)</b>	<b>9.2</b>	

## Appendix 2 – Reconciliation of Net Profit/(loss) after tax to Underlying EBITDA and Net profit after tax before significant items



	1H17 \$'000	1H16 \$'000
<b>Net profit after tax from continuing operations as reported</b>	<b>2,379</b>	<b>(812)</b>
Income tax/(benefit) expense	178	(519)
Depreciation and amortisation	1,787	851
Finance costs (net)	957	599
Rent expense	6,935	5,280
Acquisition activity expenses and associated costs (note 1)	1,527	1,635
Deferred consideration adjustment (note 2)	(2,341)	-
Ramp-up costs - Gold Coast Surgical Hospital (note 3)	1,377	1,381
<b>EBITDA-R</b>	<b>12,799</b>	<b>8,415</b>
Rent paid (note 4)	(5,594)	(3,892)
<b>EBITDA</b>	<b>7,205</b>	<b>4,523</b>
Depreciation and amortisation (note 4)	(1,073)	(587)
<b>EBIT</b>	<b>6,132</b>	<b>3,936</b>
Finance costs (net)	(957)	(599)
<b>Profit before tax</b>	<b>5,175</b>	<b>3,337</b>
Income tax expense (note 4)	(1,247)	(397)
<b>Net profit after tax from continuing operations</b>	<b>3,928</b>	<b>2,940</b>

For the first half of 2017 the following significant and non-recurring expenses were incurred:

Note 1.

During the period the Company incurred costs of \$1.527m associated with the acquisition of Australian and New Zealand sites and costs associated with the Health Care scheme of arrangement.

Note 2.

The fair value of contingent consideration for The Hills Clinic was adjusted by \$520k, and the fair value of contingent consideration for Zenitas Holdings (Hobson/Healthwoods) was adjusted by \$1.821m.

Note 3.

Ramp-up losses associated with the greenfield hospital on the Gold Coast, opened on the 31 August 2015.

Note 4.

Excludes greenfield hospital costs.



# Pulse

## Important Notice

The purpose of the presentation is to provide an update of the business of Pulse Health Ltd (ASX:PHG). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by Pulse Health Ltd and should not be relied upon as an independent source of information. Please contact Pulse Health Ltd and/or refer to the Company's website for further information.

The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. None of Pulse Health Ltd, or any of its affiliates or associated companies (or any of their officers, employees, contractors or agents (the Relevant Persons)) makes any representation or warranty as to the accuracy, completeness or reliability of the information, or the likelihood of fulfilment of any forward looking statement or any outcomes expressed or implied in any forward looking statements. Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Pulse Health Ltd's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and Pulse Health Ltd's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution. Except as required by applicable law or the ASX listing rules, the Relevant Persons disclaim any obligation or undertaking to publicly update any statements in this presentation, whether as a result of new information or future events. This presentation should not be relied on as a recommendation or forecast by Pulse Health Ltd. Nothing in this presentation constitutes investment advice or should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.